Interní Med. 2007; 9(2): 96-98

Nízkomolekulární hepariny v terapii akutních koronárních syndromů

MUDr. Pavel Sedloň2, MUDr. Kateřina Ševčíková1, MUDr. Ilja Kotík2, MUDr. Ivan Jeřábek2
1 Kardiologické oddělení, Interní klinika 1. LF UK a ÚVN, Praha
2 I. interní odd. s JIP, Ústřední vojenská nemocnice Praha

Jednou z hlavních součástí terapie akutních koronárních syndromů (ACS) je terapie nízkomolekulárními hepariny (LMWH). Tato terapie má řadu výhod proti standardně užívané léčbě nefrakcionovaným heparinem, především spolehlivější predikci účinku, jednodušší způsob podávání a nižší riziko vzniku heparinem indukované trombocytopenie. V našich podmínkách patří k nejčastěji užívaným preparátům nadroparin, dalteparin a enoxaparin. Z dat klinických studií je možno odvozovat, že tyto preparáty nejsou v indikaci terapie ACS zcela ekvipotentní, nejlépe doloženo je užití enoxaparinu. Vzhledem k tomu, že se často setkáváme s tlakem na použití jiných preparátů v této indikaci z ekonomických důvodů, provedli jsme na našem pracovišti jednoduché srovnání užití nadroparinu v multi balení po 5 ml a eno­xaparinu v předplněných stříkačkách. Jako ekonomicky výhodnější se zdá užívání enoxaparinu, tento preparát tedy i z farmakoenomického hlediska považujeme za lék volby v indikaci terapie ACS.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sedloň P, Ševčíková K, Kotík I, Jeřábek I. Nízkomolekulární hepariny v terapii akutních koronárních syndromů. Interní Med. 2007;9(2):96-98.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anand SS, Yusuf S, Pogue J, et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003; 107: 2884-2888. Go to original source... Go to PubMed...
    2. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non Q wave myocardial infarction. Results of the trombolysis in myocardial infarction (TIMI) 11B Trial. Circulation 1999; 100: 1593-1601. Go to original source... Go to PubMed...
    3. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006 Apr 6; 354 (14): 1477-1488. Epub 2006 Mar 14. Go to original source... Go to PubMed...
    4. Califf RM, Petersen JL, Hasselblad V, et al. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non ST elevation acute coronary syndromes. Am J Heart J. 2005; 149 (4 Suppl): S91-99. Go to original source... Go to PubMed...
    5. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, et al. Low-molecular-weight heparins in non ST segment elevation ischemia: The ESSENCE trial. Am J Cardiol 1998; 82: 19-24L. Go to original source... Go to PubMed...
    6. de Lemos JA, Blazing MA, Wiviott SD, et al. Enoxaparin vs unfractionated heparin in patients treated with tirofiban aspirin an earty conservative initial managment startegy: results from the A phaze of the A to Z trial. Eur J Heart 2004; 25: 1688-1694. Go to original source... Go to PubMed...
    7. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high risc patients with non ST segment elevation syndromes managed with an intended earty invasive strategy: primary results of the SYNERGY randomised trial. J Am Med Assoc 2004; 292: 45-54. Go to original source...
    8. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeksin the managment of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61-68. Go to original source... Go to PubMed...
    9. STEEPLE, N Engl J Med 2006; 355: 1006-1017. Go to original source... Go to PubMed...
    10. The FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568. Go to original source...
    11. The FRAXIS Investigators. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial managment of unstable angina pectoris or non Q wave myocardial infarction: FRAXIS (FRAxiparine in Ischemic Syndrome). Eu Heart J. 1999; 20: 1553-1562. Go to original source... Go to PubMed...
    12. Wong CG, Giugliano RP, Antman EM, et al. Use of low-molecular-weight heparins in the managment of acute coronary syndromes and percutaneous coronary intervention. JAMA, 2003; 289: 331-342. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.